Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. 2013

Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
Elemental Bio-imaging Facility, University of Technology Sydney, New South Wales, Australia. dominic.hare@uts.edu.au

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a potent toxin used to selectively destroy dopaminergic neurons in the substantia nigra and induce parkinsonism. MPTP is metabolised to the 1-methyl-4-phenylpyridinium ion (MPP(+)) in glia, after which it enters the neuron via the dopamine transporter and results in elevated levels of oxidative stress. The mechanism through which MPP(+) causes cell death is thought to involve redox-active metals, particularly iron (Fe). This review will examine how cellular metal metabolism is altered following MPTP insult, and how this relates to metal dyshomeostasis in idiopathic Parkinson's disease. This includes both cell damage arising from increased metal concentration, and how metal-binding proteins respond to MPTP-induced neurotoxicity. Implications for using MPTP as a model for human Parkinson's disease will be discussed in terms of cell metallobiology.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D015632 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. MPTP,N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
D020267 MPTP Poisoning A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8) MPTP Neurotoxicity Syndrome,MPTP-Induced Degeneration of the Striatum,MPTP-Induced Parkinsonism,Neurotoxicity Syndrome, MPTP,Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine,MPTP Induced Degeneration of the Striatum,MPTP Induced Parkinsonism,MPTP Neurotoxicity Syndromes,Neurotoxicity Syndromes, MPTP,Parkinsonism, MPTP-Induced,Poisoning, MPTP

Related Publications

Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
February 1992, Journal of neurochemistry,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
December 2005, Neurobiology of disease,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
September 2009, Antioxidants & redox signaling,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
March 1990, Neuropharmacology,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
June 1990, Biochemical Society transactions,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
January 1994, Journal of neurochemistry,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
January 2006, Nutritional neuroscience,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
January 1997, Neurochemical research,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
January 2006, Journal of applied genetics,
Dominic J Hare, and Paul A Adlard, and Philip A Doble, and David I Finkelstein
January 1987, Ciba Foundation symposium,
Copied contents to your clipboard!